Contribution of Yeast Models to Neurodegeneration Research
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
As a model organism Saccharomyces cerevisiae has greatly contributed to our understanding of many fundamental aspects of cellular biology in higher eukaryotes. More recently, engineered yeast models developed to study endogenous or heterologous proteins that lay at the root of a given disease have become powerful tools for unraveling the molecular basis of complex human diseases like neurodegeneration. Additionally, with the possibility of performing target-directed large-scale screenings, yeast models have emerged as promising first-line approaches in the discovery process of novel therapeutic opportunities against these pathologies. In this paper, several yeast models that have contributed to the uncovering of the etiology and pathogenesis of several neurodegenerative diseases are described, including the most common forms of neurodegeneration worldwide, Alzheimer's, Parkinson's, and Huntington's diseases. Moreover, the potential input of these cell systems in the development of more effective therapies in neurodegeneration, through the identification of genetic and chemical suppressors, is also addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138 · cited 1×
“This can also explain the forefront position of yeast in the development of large scale screening approaches, like DNA and protein microarrays [1–3], two-hybrid analysis [4, 5], and whole-genome deletion and overexpression libraries [6, 7].”
BackgroundIntracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Global Analysis of Protein Activities Using Proteome Chips
Zhu, H., Bilgin, M., Bangham, R., Hall, D., Casamayor, A., Bertone, P., Lan, N., Jansen, R., Bidlingmaier, S., Houfek, T., et al. (2001) · Science · doi:10.1126/science.1062191 · Cited by 1,884 · cited 1×
“Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2012, Article ID 941232, 12 pages doi:10.1155/2012/941232”
BackgroundInfluentialThe Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060 · cited 1×
“Despite its toxicity, recent evidence suggests that increased amounts of Aβ peptide may have a normal function as an antimicrobial peptide [38].”
BackgroundRegulation of Mitochondrial Iron Accumulation by Yfh1p, a Putative Homolog of Frataxin
Babcock, M., de Silva, D., Oaks, R., Davis-Kaplan, S., Jiralerspong, S., Montermini, L., Pandolfo, M., & Kaplan, J. (1997) · Science · doi:10.1126/science.276.5319.1709 · Cited by 921
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715 · cited 1×
“With the increase in life expectancy, neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases became major health problems in our society for which treatments are critically required [9].”
BackgroundSchulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Regulation of RAD53 by the ATM -Like Kinases MEC1 and TEL1 in Yeast Cell Cycle Checkpoint Pathways
Sanchez, Y., Desany, B. A., Jones, W. J., Liu, Q., Wang, B., & Elledge, S. J. (1996) · Science · doi:10.1126/science.271.5247.357 · Cited by 585 · cited 2×
“Ataxia-telangiectasia ATM TEL1, MEC1 [19, 20]”
BackgroundYeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein
Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L., & Muchowski, P. J. (2003) · Science · doi:10.1126/science.1090389 · Cited by 422 · cited 3×
“A genetic screening of a collection of deleted nonessential genes led to the identification of several mutants with enhanced α-synuclein toxicity [69].”
BackgroundTreusch, S., Hamamichi, S., Goodman, J. L., Matlack, K. E. S., Chung, C. Y., Baru, V., Shulman, J. M., Parrado, A., Bevis, B. J., Valastyan, J. S., et al. (2011) · Science · doi:10.1126/science.1213210 · Cited by 379
The kynurenine pathway of tryptophan degradation as a drug target
Schwarcz, R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.006 · Cited by 265
Bayer (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00008 · Cited by 252
Keller, J. (2002) · Ageing Research Reviews · doi:10.1016/s1568-1637(01)00006-x · Cited by 247
Cited by
Alternatives to animal testing: a review
Doke, S. K., & Dhawale, S. C. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.11.002 · Cited by 564
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
Marquez-Lona, E. M., Torres-Machorro, A. L., Gonzales, F. R., Pillus, L., & Patrick, G. N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179893 · Cited by 17
“S . cerevisiae has proven to be an excellent organism in which to study molecular mechanistic aspects of human neurodegenerative disease [28, 64].”
Metadata
- Authors
- Pereira, C., Bessa, C., Soares, J., Leão, M., & Saraiva, L.
- Venue
- Journal of Biomedicine and Biotechnology
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-12
- ISSN
- 1110-7243 (ISSN-L)
- 1110-7251
- OpenAlex
- W2155711352
- Cited by
- 55
- References
- 14
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.